These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38559216)

  • 21. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
    Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.
    Gayed J; Bangad V; Xu X; Mensa F; Cutler M; Türeci Ö; Şahin U; Modjarrad K; Swanson KA; Anderson AS; Gurtman A; Kitchin N;
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
    J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM
    J Virol; 2024 Oct; 98(10):e0052824. PubMed ID: 39230305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC
    J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
    Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Aug; 15(8):e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
    Wang Q; Guo Y; Bowen A; Mellis IA; Valdez R; Gherasim C; Gordon A; Liu L; Ho DD
    Cell Host Microbe; 2024 Mar; 32(3):315-321.e3. PubMed ID: 38377995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
    Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Jian F; Wang J; Yisimayi A; Song W; Xu Y; Chen X; Niu X; Yang S; Yu Y; Wang P; Sun H; Yu L; Wang J; Wang Y; An R; Wang W; Ma M; Xiao T; Gu Q; Shao F; Wang Y; Shen Z; Jin R; Cao Y
    Nature; 2024 Nov; ():. PubMed ID: 39510125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
    Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
    Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
    Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.